Yeah the short position has been stable recently.
I still can't get over we're down nearly twice as much as Acadia in the last month.
Acadia is far more reliant on Daybue short term revenue given Nuplazid indication use, will not be expanded after their failed Phase 3 result in March for schizophrenia. Then there's the matter of three good NNZ-2591 results for Neuren.
What are we missing?
Share Price, page-11189
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
-0.330(2.07%) |
Mkt cap ! $2.027B | |||
| Open | High | Low | Value | Volume |
| $16.25 | $16.32 | $15.55 | $8.397M | 528.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38 | $17.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.05 | 7415 | 1 |
View Market Depth
| Last trade - 15.59pm 14/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |